TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35927684

Group type: EXPERIMENTAL
Intervention: ALAPAGE program (combined diet/physical activity intervention)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: ALAPAGE program
Number of subjects: 450
Study: 35927710

Group type: EXPERIMENTAL
Intervention: Intralesional T-VEC (up to 4 mL, first dose as seroconversion dose) and systemic nivolumab (240 mg flat dose) every 2 weeks for four courses of T-VEC and three doses of nivolumab
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intralesional T-VEC and systemic nivolumab
Number of subjects: 24
Study: 35927713

Group type: EXPERIMENTAL
Intervention: Malaria care interventions during the COVID-19 pandemic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment and use of insecticide-treated nets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of genetic markers of resistance to artemisinin derivatives and sulfadoxine-pyrimethamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective, interrupted-time series analysis
Number of subjects: 0
Study: 35927795

Group type: EXPERIMENTAL
Intervention: Whole-room indirect calorimeters
Number of subjects: 16
Study: 35928271

Group type: EXPERIMENTAL
Intervention: Urinary aromatic amino acid metabolites
Number of subjects: 0
Study: 35928510

Group type: EXPERIMENTAL
Intervention: Telerehabilitation program (Future Patient Program)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 137
Study: 35928870

Group type: EXPERIMENTAL
Intervention: UCPVax (therapeutic cancer vaccine composed of two peptides derived from telomerase) combined with atezolizumab (anti-PD-L1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 0
Study: 35928890

Group type: COMPARATOR
Intervention: Sarcopenic obesity (SO) in patients with neurodisabilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: BMI and SMI scores in patients with neurodisabilities
Number of subjects: 0
Study: 35928938

Group type: EXPERIMENTAL
Intervention: Personalized Algorithm for Severe Atheromatosis Prediction (PASAP-ILERVAS)
Number of subjects: 0
Study: 35928993

Group type: EXPERIMENTAL
Intervention: Speed of Processing (SoP) training plus alpha transcranial alternating current stimulation (α-tACS)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Speed of Processing (SoP) training alone
Number of subjects: 327

Group type: COMPARATOR
Intervention: Active alpha transcranial alternating current stimulation (α-tACS) alone
Number of subjects: 327

Group type: COMPARATOR
Intervention: Sham alpha transcranial alternating current stimulation (α-tACS)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Speed of Processing (SoP) training plus α-tACS
Number of subjects: 327
Study: 35929414

Group type: EXPERIMENTAL
Intervention: EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Number of subjects: 0
Study: 35929455

Group type: EXPERIMENTAL
Intervention: Insulin receptor substrate-1 rs956115 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYP2C19 rs4244285 genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35929787

Group type: EXPERIMENTAL
Intervention: LMCAD present
Number of subjects: 2510

Group type: COMPARATOR
Intervention: LMCAD absent
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: LMCAD present (after propensity score matching)
Number of subjects: 2510

Group type: COMPARATOR
Intervention: LMCAD absent (after propensity score matching)
Number of subjects: 2510
Study: 35929986

Group type: EXPERIMENTAL
Intervention: AZD5305 at doses ≥0.1 mg/kg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olaparib 100 mg/kg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD5305
Number of subjects: 0
Study: 35930017

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced computed tomography (CE-CT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 68 Gallium-DOTATOC positron emission tomography (68 Ga-DOTATOC PET)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nodal metastases identification at ≥1 imaging technique
Number of subjects: 100
Study: 35930078

Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopic hematoma evacuation (MEHE)
Number of subjects: 0
Study: 35930301

Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 574
Study: 35930331

Group type: EXPERIMENTAL
Intervention: Intermittent Fasting Healthy Plate (IFHP)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Healthy Plate (HP)
Number of subjects: 177
Study: 35930336

Group type: EXPERIMENTAL
Intervention: Passive mobile sensing using a mobile app for tracking activity, sociability, and sleep in patients with SMI over 9 months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly assessments during the mobile sensing phase for 9 months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician interviews before and after the mobile sensing phase.
Number of subjects: 0
Study: 35930351

Group type: EXPERIMENTAL
Intervention: WIC plus biweekly grocery delivery
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: WIC plus biweekly grocery and unsweetened beverage delivery
Number of subjects: 855

Group type: COMPARATOR
Intervention: Usual care from WIC (control)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 855
Study: 35930353

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2498
Study: 35930441

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) with US-responsive carriers
Number of subjects: 0
Study: 35930750

Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vemurafenib retreatment
Number of subjects: 36
Study: 35930972

Group type: EXPERIMENTAL
Intervention: selpercatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: pemetrexed + platinum (KEYNOTE-189)
Number of subjects: 0
Study: 35931001

Group type: EXPERIMENTAL
Intervention: Delayed Graft Function (DGF)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Hypertensive Nephropathy
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Cold Ischemia Time (CIT)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: DGF in body artery stenosis subgroup
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) in body artery stenosis subgroup
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Multivariable model for TRAS risk prediction
Number of subjects: 274
Study: 35931041

Group type: EXPERIMENTAL
Intervention: Ketamine infusions (0.5 mg/kg over 40 minutes)
Number of subjects: 38
Study: 35931285

Group type: EXPERIMENTAL
Intervention: Chelation therapy for divalent metals (lead and cadmium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chelation therapy (TACT2 trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 0
Study: 35931600

Group type: EXPERIMENTAL
Intervention: Immediate medical treatment (IMT) started less than 3 months after metastatic diagnosis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Delayed medical treatment (DMT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Local treatment of metastasis (LTM)
Number of subjects: 90
Study: 35931943

Group type: EXPERIMENTAL
Intervention: Tucatinib 300 mg dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steady-state tucatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tucatinib
Number of subjects: 0
Study: 35932306

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrate (BMC)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: BMC injections with higher CFU-F concentrations
Number of subjects: 65
Study: 35932313

Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tube (BDET)
Number of subjects: 28
Study: 35932387

Group type: EXPERIMENTAL
Intervention: Envafolimab 1.0 mg/kg, 2.5 mg/kg, and 5.0 mg/kg SC QW (10 patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Envafolimab 2.5 mg/kg and 5.0 mg/kg SC Q2W (16 patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Envafolimab 300 mg SC Q4W (9 patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Envafolimab
Number of subjects: 35
Study: 35932388

Group type: EXPERIMENTAL
Intervention: Pevonedistat (50 mg/m)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 0
Study: 35932543

Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other exposures (rural exposures, pesticide exposures)
Number of subjects: 0
Study: 35932628

Group type: EXPERIMENTAL
Intervention: Nilotinib treatment
Number of subjects: 48
Study: 35932876

Group type: EXPERIMENTAL
Intervention: Universal cervical length screening program
Number of subjects: 3468

Group type: EXPERIMENTAL
Intervention: Cervical length screening
Number of subjects: 3468

Group type: EXPERIMENTAL
Intervention: Asymptomatic short cervix treatment (200 mg vaginal progesterone, cerclage, or pessary)
Number of subjects: 3468

Group type: EXPERIMENTAL
Intervention: ECHOCOL cohort
Number of subjects: 3468
Study: 35932937

Group type: EXPERIMENTAL
Intervention: Nēsos wearable, non-invasive, transcutaneous auricular vagus nerve stimulation (taVNS) system
Number of subjects: 25
Study: 35932960

Group type: COMPARATOR
Intervention: PDT only (20% ALA, 15 min; blue light 417 nm, 30 min)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PDT with sandpaper curettage
Number of subjects: 66
Study: 35933358

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment 2 g/kg monthly for three months
Number of subjects: 10
Study: 35933434

Group type: EXPERIMENTAL
Intervention: L2P2 writing intervention (three 7-min sessions over 5 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L2P2 writing intervention
Number of subjects: 20
Study: 35933552

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35933560

Group type: EXPERIMENTAL
Intervention: Text-messaging intervention for unhealthy alcohol use (UAU)
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Implementation strategy for text-messaging intervention
Number of subjects: 11000
Study: 35933915

Group type: EXPERIMENTAL
Intervention: Cobicistat co-administration with osimertinib
Number of subjects: 11

Group type: COMPARATOR
Intervention: Osimertinib alone
Number of subjects: 11
Study: 35934010

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg IV) plus tremelimumab (75 mg IV) for four cycles, followed by durvalumab alone every 4 weeks for up to 12 months.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 62
Study: 35934286

Group type: EXPERIMENTAL
Intervention: Post-induction fecal calprotectin (FCP) concentration of ≤250 μg/g
Number of subjects: 1391
Study: 35934287

Group type: EXPERIMENTAL
Intervention: Cilofexor 100 mg daily
Number of subjects: 47
Study: 35934563

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) in female patients
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) in male patients
Number of subjects: 1644
Study: 35934650

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) during laceration repair
Number of subjects: 40
Study: 35934726

Group type: EXPERIMENTAL
Intervention: Ig20Gly
Number of subjects: 125
Study: 35934926

Group type: EXPERIMENTAL
Intervention: ANNE sleep system
Number of subjects: 225

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 225
Study: 35935359

Group type: EXPERIMENTAL
Intervention: Family supportive EOLC intervention group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard EOLC group
Number of subjects: 45
Study: 35935379

Group type: EXPERIMENTAL
Intervention: AIDA International Registry for PFAPA patients
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Data recruitment through the on-line Research Electronic Data Capture (REDCap) tool
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Collection of PFAPA patient's demographics, medical histories, symptoms, triggers/risk factors, therapies, and impact on healthcare systems
Number of subjects: 321
Study: 35935445

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine (0.75 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram (15 mg) and aripiprazole (5 mg)
Number of subjects: 0
Study: 35935625

Group type: EXPERIMENTAL
Intervention: HTI assay
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 301
Study: 35935634

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i) administered to Group I with inadequately controlled T2D (mean fasting plasma glucose (FPG) of ≥7 mmol/L)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 450

Group type: COMPARATOR
Intervention: Adequately controlled T2D (mean FPG of <7 mmol/L)
Number of subjects: 450

Group type: COMPARATOR
Intervention: No diabetes (mean FPG of ≤ 5.5 mmol/L)
Number of subjects: 450
Study: 35935714

Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study: 35935775

Group type: EXPERIMENTAL
Intervention: Perioperative hemodynamic optimization protocol based on uncalibrated pulse-contour analysis.
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual standard of care (Control group).
Number of subjects: 172
Study: 35935785

Group type: EXPERIMENTAL
Intervention: New integrated weaning indices
Number of subjects: 1175
Study: 35935821

Group type: EXPERIMENTAL
Intervention: Capecitabine plus Oxaliplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine plus Oxaliplatin
Number of subjects: 0
Study: 35935856

Group type: EXPERIMENTAL
Intervention: Camostat Mesylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir
Number of subjects: 0
Study: 35935863

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (2 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35935974

Group type: COMPARATOR
Intervention: BNT162b2 Pfizer-BioNTech vaccine
Number of subjects: 150
Study: 35936328

Group type: EXPERIMENTAL
Intervention: 30-15 intermittent fitness test
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2-mile run
Number of subjects: 32
Study: 35936702

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 35937420

Group type: EXPERIMENTAL
Intervention: Electronic adherence monitors with optional SMS messages and alarms
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 51
Study: 35937495

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35937937

Group type: COMPARATOR
Intervention: MPG-Luminex Assay
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Anyplex™ II HPV HR Detection assay
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: EUROArray HPV Assay
Number of subjects: 110
Study: 35938130

Group type: EXPERIMENTAL
Intervention: Mg + B vitamins + green tea + rhodiola
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rhodiola in isolation
Number of subjects: 100
Study: 35938182

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35938460

Group type: EXPERIMENTAL
Intervention: Patient-centered risk mitigation approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further research into optimal prevention approaches for CVD among WLWH
Number of subjects: 0
Study: 35938545

Group type: EXPERIMENTAL
Intervention: Bipolar Androgen Therapy (BAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar Androgen Therapy (BAT) followed by abiraterone or enzalutamide
Number of subjects: 0
Study: 35938625

Group type: EXPERIMENTAL
Intervention: Arthroscopic shoulder surgery
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Glenohumeral stabilisation
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Frozen shoulder release
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Pulmonary embolism
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Reoperation within one year
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Further surgery for deep infection after rotator cuff repair
Number of subjects: 261248

Group type: EXPERIMENTAL
Intervention: Further surgery for deep infection overall
Number of subjects: 261248
Study: 35938699

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 176
Study: 35939260

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of quadriceps femoris muscle thickness (MT) in non-contraction (non-con) situation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of quadriceps femoris muscle thickness (MT) in contraction (con) situation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of muscle echo intensity (MEI) in non-contraction (non-con) situation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Blood and urinary biomarkers
Number of subjects: 76
Study: 35939367

Group type: EXPERIMENTAL
Intervention: Antiseizure medications (ASMs)
Number of subjects: 1341509

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1341509

Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 1341509

Group type: EXPERIMENTAL
Intervention: Drug-drug interactions between ASMs
Number of subjects: 1341509
Study: 35939663

Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise 3 times a week for 4 weeks
Number of subjects: 24
Study: 35939770

Group type: EXPERIMENTAL
Intervention: NGS-based genomic profiling and multidisciplinary case discussions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WAYFIND-R registry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: User-friendly electronic case report forms and standardized collection of molecular tumor board-based decisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global collaborations between cancer centers
Number of subjects: 0
Study: 35939785

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 133
Study: 35939812

Group type: EXPERIMENTAL
Intervention: Opioid Agonist Therapy (OAT)
Number of subjects: 296
Study: 35939919

Group type: EXPERIMENTAL
Intervention: Manual therapy program (MTP) applied to craniomandibular structures, four weekly sessions
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Manual therapy program (MTP)
Number of subjects: 102
Study: 35939981

Group type: EXPERIMENTAL
Intervention: Lesion Regression (LR) group
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lesion Progression (LP) group
Number of subjects: 161
Study: 35940054

Group type: EXPERIMENTAL
Intervention: Sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Initial combination of fluoropyrimidine, irinotecan, and bevacizumab (Arm B)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sequential treatment in patients older than 70 years
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sequential treatment in patients with RAS mutant tumours
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Combination treatment in RAS/BRAF wild-type tumours
Number of subjects: 421
Study: 35940055

Group type: EXPERIMENTAL
Intervention: TQ-B3139 (50-800 mg) administered continuously in 28-day cycles, with expansion stage starting at 200 mg BID.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: TQ-B3139 at dose level ≥200 mg BID.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: TQ-B3139 in patients with measurable brain metastases.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: TKI-treated patients with variant 3 and TP53 alteration.
Number of subjects: 63
Study: 35940085

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (12 sessions over six weeks including bilateral unweighted squats with visual and tactile biofeedback)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention control group (six-week educational program)
Number of subjects: 40
Study: 35940183

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus vemurafenib plus cobimetinib
Number of subjects: 65
Study: 35940334

Group type: EXPERIMENTAL
Intervention: COVID group
Number of subjects: 0
Study: 35940825

Group type: EXPERIMENTAL
Intervention: Varlilumab (0.1-10 mg/kg) with nivolumab (3 mg/kg) administered once every 2 weeks (Phase 1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Varlilumab (3 mg/kg once every 2 weeks, 3 mg/kg once every 12 weeks, and 0.3 mg/kg once every 4 weeks) with nivolumab (240 mg once every 2 weeks) (Phase 2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Varlilumab and nivolumab combination
Number of subjects: 175
Study: 35940836

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (up to 20 mg) and glyceryl trinitrate (GTN) (0.8 mg and 0.4 mg)
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Reduced GTN doses
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Intravenous beta-blocker administration
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: GTN dose reduction
Number of subjects: 5500
Study: 35940871

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) applied as four cycles of ischaemia (4 min) followed by reperfusion (4 min) and a 5 min gap, repeated on two consecutive days.
Number of subjects: 15
Study: 35941015

Group type: EXPERIMENTAL
Intervention: Postoperative pain treatment
Number of subjects: 189
Study: 35941023

Group type: EXPERIMENTAL
Intervention: StrataGraft
Number of subjects: 101
Study: 35941028

Group type: EXPERIMENTAL
Intervention: Trastuzumab (loading dose 8 mg/kg, then 6 mg/kg every 3 weeks) and oral pyrotinib (400 mg per day until progression)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trastuzumab and pyrotinib
Number of subjects: 16